CYP2C8 and cancer: This discovery harmonizes with existing evidence indicating lestaurtinib inhibitory effects on CYP2C8 and CYP3A activity.[30] Furthermore, the association between lestaurtinib and the “Loss of Function of TP53 in Cancer” pathway is substantiated by a recent study that lestaurtinib could induces cell cycle arrest, apoptosis, and activates the TP53 superfamily within medulloblastoma cells.[31]